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Abstract
Background: Macrophage infiltration in adipose tissue together with the aberrant production of pro-inflammatory
cytokines has been identified as the key link between obesity and its related metabolic disorders. This study aims
to isolate bioactive ingredients from the traditional Chinese herb Radix Astragali (Huangqi) that alleviate obesity-
induced metabolic damage through inhibiting inflammation.
Methods: Active fraction (Rx) that inhibits pro-inflammatory cytokine production was identified from Radix
Astragali by repeated bioactivity-guided high-throughput screening. Major constituents in Rx were identified by
column chromatography followed by high-performance liquid chromatography (HPLC) and mass-spectrometry.
Anti-diabetic activity of Rx was evaluated in db/db mice.
Results: Treatment with Rx, which included calycosin-7-b-D-glucoside (0.9%), ononin (1.2%), calycosin (4.53%) and
formononetin (1.1%), significantly reduced the secretion of pro-inflammatory cytokines (TNF-a, IL-6 and MCP-1) in
human THP-1 macrophages and lipopolysaccharide (LPS)-induced activation of NF-B in mouse RAW-Blue
macrophages in a dose-dependent manner. Chronic administration of Rx in db/db obese mice markedly decreased
the levels of both fed and fasting glucose, reduced serum triglyceride, and also alleviated insulin resistance and
glucose intolerance when compared to vehicle-treated controls. The mRNA expression levels of inflammatory cell
markers CD68 and F4/80, and cytokines MCP-1, TNF-a and IL-6 were significantly reduced in epididymal adipose
tissue while the alternatively activated macrophage marker arginase I was markedly increased in the Rx-treated
mice.
Conclusion: These findings suggest that suppression of the inflammation pathways in macrophages represents a
valid strategy for high-throughput screening of lead compounds with anti-diabetic and insulin sensitizing
properties, and further support the etiological role of inflammation in the pathogenesis of obesity-related
metabolic disorders.
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Background
Obesity is a major risk factor for a cluster of cardio-
metabolic disorders including insulin resistance, fatty
liver, dyslipidemia, type 2 diabetes and cardiovascular
diseases [1,2]. Mounting evidence suggests that low-
grade systemic chronic inflammation plays an important
role in linking obesity to its associated pathologies.
Adipose tissue, originally regarded as an inert energy
storage compartment, is now found to be an endocrine
organ that secretes a large number of adipokines to reg-
ulate energy balance, food intake, lipid and glucose
metabolism, insulin sensitivity and vascular tone [3]. It
also plays a pivotal role in the development of systemic
inflammation in obese subjects [4]. In obese humans
and rodents, increased infiltration of activated macro-
phages or mast cells into adipose tissues is clearly evi-
dent [5]. Enlarged adipocytes, together with the
infiltrated macrophages, act in a synergistic manner to
cause aberrant production of pro-inflammatory mole-
cules including inducible nitric oxide, cytokines such as
tumor necrosis factor-alpha (TNF-a), interleukine-6 (IL-
6) and the chemokine monocyte chemoattractant pro-
tein-1 (MCP-1). Both TNF-a and IL-6 can impede insu-
lin sensitivity by triggering different key steps in the
insulin signaling pathway [6-8]. Meanwhile, chronic
inflammation impacts on the fat storage in adipose tis-
sue, resulting in excess free fatty acid and triglycerides
in the bloodstream, and the induction of insulin resis-
tance in muscle and liver, in part via ectopic fat deposi-
tion in these tissues [1,9,10]. Weight loss has been
shown to result in a reduction in macrophage accumula-
tion and ameliorate the up-regulated inflammatory
status in humans [11,12].
Radix Astragali, which is known as Huangqi in Chi-
nese, is a flowering plant in the family Fabaceae. It is
one of the 50 fundamental herbs used in traditional Chi-
nese medicine and is traditionally used for the treatment
of diabetes, wound healing [13] and strengthening the
immune system [14,15]. Recently, a herbal formulation
with Radix Astragali was shown to exert anti-hypergly-
cemic and anti-oxidant effect in the db/db diabetic
mouse model [16]. In addition, our laboratory has
demonstrated the anti-diabetic effect of two natural
compounds from Radix Astragali, astragaloside II and
isoastragaloside I, which can enhance the expression of
adiponectin, an insulin-sensitizing adipokine [17]. How-
ever, the detailed mechanism underlying the anti-dia-
betic effects of Radix Astragali remains poorly
understood.
Since the dysregulated production of cytokines and
the activation of the inflammatory signaling pathways
are closely associated with obesity-related metabolic dis-
eases, we postulated that the beneficial metabolic effect
of Radix Astragali may be mediated through anti-inflam-
matory actions. In this study, Radix Astragali was frac-
tionated and its constituents were repeatedly screened
for their activities in inhibiting pro-inflammatory cyto-
kine production and lipopolysaccharide (LPS)-induced
activation of the NF-B signaling pathway in macro-
phages. The therapeutic potential of the selected active
fraction Rx on the obesity-related metabolic disorders
was validated in the db/db diabetic mice.
Materials and methods
Preparation of Bioactive Extracts from the Plant materials
Radix Astragali, the dried root of Astragalus membrana-
ceus Bge. var.mongholicus (Bge.) Hsiao, was collected
from Rui-Bao Good Agriculture Practice (GAP) base at
Baotou City of Inner Mongolia in China in April 2008. A
voucher specimen has been deposited in the Chinese
Medicine Laboratory of Hong Kong Jockey Club Institute
of Chinese Medicine. Radix Astragali was powdered and
extracted with ethanol (20%, 50%, 80% and 95%) and
water. The extract evaporated in vacuum and used for
high-throughput screening. The effective fractions that
inhibited pro-inflammatory cytokine production in
macrophages was further extracted with various organic
solvents (butanol and ethyl acetate) and their anti-inflam-
matory activities were further determined. To identify the
major constituents in selected active fraction Rx, HPLC
was performed in an Agilent 1100 system comprising of
a quaternary pump, an online degasser, an auto-sampler,
a column heater and a variable wavelength detector.
Separation was achieved on a 4.6 × 250 mm, 5 μm parti-
cle, Alltima C18 reversed-phase analytical column. The
mobile phase was acetonitrile and 0.1% aqueous formic
acid; the amount of acetonitrile was changed linearly
from 10 to 60% in 40 min. The flow rate was 1.0 ml/min
and the wavelength was 254 nm. The proposed method
for quantitative analysis of major constituents in the
bioactive extracts was validated in terms of linearity, lim-
its of detection and quantification, reproducibility and
recovery. The identified active fraction was used for the
treatment of db/db diabetic mice.
Cell Culture and Macrophage Differentiation
Human THP-1 macrophage cells were maintained as
sub-confluent cultures in RPMI-1640 supplemented
with 10% fetal bovine serum and were induced for dif-
ferentiation by incubating with 100 nM phorbol 12-myr-
istate 13-acetate (PMA) for 3 days. After differentiation,
medium was replaced with RPMI-1640 with 10% fetal
bovine serum for 1 day before drug treatment. RAW-
Blue cells (InvivoGen) were murine macrophages
derived from RAW 264.7 cells. RAW-Blue cells were
maintained as sub-confluent cultures in DMEM
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supplemented with 10% fetal bovine serum (Invitrogen).
Cells were seeded in 24-well plate 1 day before drug
treatment.
Quantification of TNF-a, MCP-1 and IL-6 Production in
Rx-treated Human THP-1 Macrophage Culture Medium
Conditioned THP-1 medium was collected after Rx
(5 μg/ml or 10 μg/ml) or Rosiglitazone (10 μg/ml) treat-
ment for 48 hours. The concentrations of TNF-a, MCP-
1 and IL-6 were determined using in-house sandwich
ELISA. The capture antibodies and detection antibodies
of human TNF-a, MCP-1 and IL-6 were purchased
from R & D systems (Minneapolis, MN).
Detection and Quantification of LPS-induced Alkaline
Phosphotase (SEAP) Activity in the Supernatants of RAW-
Blue Cells
RAW-Blue cells were treated with LPS (100 ng/ml)
alone or together with Rx (10 μg/ml or 20 μg/ml) for 24
or 48 hours. SEAP activity in the conditioned medium
was determined using QUANTI-Blue medium
(InvivoGen) following manufacturer’s manual. Briefly,
20 μl samples were added to 200 μl of Quanti-Blue
assay buffer (InvivoGen) and incubated at 37 C for 15
to 30 minutes. Absorbance was measured at 620 nm
and fold change in SEAP activity in each sample com-
pared to LPS-induced sample was calculated.
Animal Studies
C57BL/KsJ db/db diabetic mice were propagated in the
laboratory animal unit at University of Hong Kong. The
mice were housed in a room under controlled tempera-
ture (23 ± 1 C), with free access to water and standard
mouse chow. Mice at the age of 10 weeks were treated
with either Rx (2 g/kg/day) or PBS with 4% Tween 80,
as control, by daily oral gavage for 12 weeks. Physical
parameters such as body weight and food intake of mice
were measured weekly. Glucose tolerance test and insu-
lin tolerance test were performed as previously
described [18]. All of the experiments were conducted
according to institutional guidelines for humane treat-
ment of laboratory animals.
Figure 1 The schematic diagram of the purification and identification of the active fractions from Radix Astragali.
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Analysis of Serum Glucose, Free fatty acid, Triglyceride
and Insulin Levels
Fed or fasting blood was collected from the tail-tip of
mice. Trunk blood was collected by cardiac puncture
under anesthesia before the mice were sacrificed. Serum
glucose level was measured using the ACCU-CHEK
Advantage II glucometer (Roche, USA). The levels of
serum triglyceride and free fatty acid were determined
using commercial assay kits Stanbio Liquicolor Triglycer-
ides (Stanbio, USA) and Half micro test (Roche, USA),
respectively. The level of insulin was measured by Ultra-
sensitive mouse insulin ELISA kit (Mercodia, Sweden).
Quantification of Inflammatory Marker Expression by
Real-time Polymerase Chain Reaction (PCR)
Total RNA was extracted from mouse epididymal fat
pads using Trizol reagent and was transcribed into
cDNA with a Superscript first-strand cDNA synthesis
system (Promega, Madison, WI, USA). The relative gene
abundance was quantified by real time PCR using the
assay on demand TaqMan primers and probes from
Applied Biosystems (Foster City, CA) with the premade
assay kits. The reactions were performed in an ABI
7000 sequence detection system.
Statistical Analysis
Statistical analyses were performed using GraphPad
Prism 3 software (San Diego, CA). Data are expressed as
means ± S.E.M. Statistical significance was determined
by one-way ANOVA and Dunnett’s post hoc test. In all
statistical comparisons, a P value < 0.05 was considered
statistically significant.
Results
High Throughput Screening of the Active Fractions from
Radix Astragali and HPLC Analysis of Four Main
Constituents in selected fraction Rx
We selected about 20 ethanol and water extracts from
three traditional Chinese herbs, Radix Astragali (Huang
Qi), Rhizoma coptids Franch (Huang Lian) and Loni-
cerae japonica Thunb. (Jin Yin Hua) to screen for the
compounds with anti-inflammatory properties. High-
throughput screening, in which various fractions were
incubated with human THP-1 for 24-48 hours followed
by ELISA assays, allowed for the identification of com-
ponents that reduced the basal cytokine secretion from
macrophages. After repeatedly screening, we identified
an active fraction (Rx) from Radix Astragali that repro-
ducibly inhibited the pro-inflammatory cytokine
Figure 2 The chemical structures of the four major constituents in the Rx and HPLC chromatogram of the Rx fraction.
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secretion from macrophages. Its anti-inflammatory
activity, as evidenced by inhibiting the NF-B signaling
pathway, was further confirmed by SEAP assay using
mouse RAW-Blue cell system. The schematic diagram
of the purification and identification of active fraction
Rx from Radix Astragali was shown in figure 1.
The HPLC analysis results showed that Rx contained
calycosin-7-b-D-glucoside (0.9%), ononin (1.2%), calyco-
sin (4.53%) and formononetin (1.1%), respectively. The
representative HPLC chromatogram was shown in figure
2.
Effect of the Fraction Rx on Secretion of Pro-
inflammatory Cytokine and LPS-induced NF-B Activation
in Macrophages
Two macrophage cell systems, human THP-1 macro-
phages and mouse RAW-Blue macrophages, were
employed in the high-throughput screening platform to
determine the effects of the active fractions. Treatment
with the selected active fraction Rx caused a drastic
reduction in secretion of pro-inflammatory cytokines
including MCP-1 and IL-6 in the conditioned medium
of THP-1 macrophages, in a dose-dependent manner
(figure 3a, b). The inhibitory effect of Rx (5 μg/ml and
10 μg/ml) on TNF-a secretion was comparable to that
of Rosiglitazone (10 μg/ml) (figure 3c). On the other
hand, Rx had a more effective inhibitory effect than
Rosiglitazone on the secretion of MCP-1 and IL-6 (fig-
ure 3a, b). The anti-inflammatory effect of Rx was
further confirmed by secondary screening using mouse
RAW-Blue cells. RAW-Blue cells are derived from
RAW-264.7 macrophages that stably express a secreted
embroyonic alkaline phosphotase (SEAP) gene which
can be induced by NF-B or AP-1 transcription factors.
Treatment of RAW-Blue cells with Rx inhibited the
LPS-induced NF-B activity in a time- and dose-depen-
dent manner as indicated by the reduced SEAP activity
(figure 4). The effect of Rx was also comparable to Rosi-
glitazone (10 μg/ml). Rx was then manufactured in a
large quantity for the in vivo study.
Effect of the Fraction Rx on Metabolic Parameters of db/
db Diabetic Mice
Having established the action of Rx on inhibiting cyto-
kine secretion from macrophages, we next validated the
therapeutic potential of the active fraction Rx in the db/
db mice, a well-established genetic obese model with
typical symptoms of type 2 diabetes. Male db/db mice
were administrated with Rx fraction (2 g/kg/day dis-
solved in 4% Tween 80 in PBS) or vehicle by daily oral
gavage for a period of 12 weeks. The effects of Rx on
insulin sensitivity and glucose metabolism were investi-
gated. Rx treatment markedly improved the glycemic
Figure 3 Rx significantly reduced the secretion of cytokines in
human THP-1 macrophages. Panels show (a) MCP-1, (b) IL-6 and
(c) TNF-a concentrations in human THP-1 macrophage conditioned
medium after incubation with Rosiglitazone (10 μg/ml) or Rx (5 μg/
ml or 10 μg/ml) for 48 hours. Each bar represents the relative mean
fold change ± SEM (n = 6). Data were statistically analyzed using
the one-way ANOVA with Dunnette’s post hoc test. * P < 0.05;
** P < 0.01.
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Figure 4 Rx significantly inhibited LPS-induced NF-B activity (as indicated by SEAP activity) in mouse RAW-Blue macrophages.
Different dosages of Rx (10 μg/ml or 20 μg/ml) or Rosiglitazone (10 μg/ml) together with 100 ng/ml LPS were incubated with RAW-Blue cells
for 24 hours or 48 hours. DMSO was used as the vehicle control. The SEAP activities in the conditioned medium of mouse RAW-Blue cells were
measured using QUANTI-Blue assay as described in Methods. Each bar represents the relative mean fold change ± SEM (n = 6). Data were
statistically analyzed using one-way ANOVA with Dunnette’s post hoc test. ** P < 0.01.
Figure 5 Rx decreased both fed and fasting blood glucose levels and alleviated hypertriglyceridemia in db/db diabetic mice. Male db/
db diabetic mice were treated with vehicle or Rx (2 g/kg/day) for 12 weeks by oral gavage. (a) The weekly profile of fed glucose levels. (b) The
fasting glucose levels at week 2, 6 and 12 measured after 16 hours of starvation. (c) Fasting serum insulin concentration after 12 weeks of Rx
treatment. (d) The weekly profile of fed triglyceride level. (e) Serum free fatty acid concentration after 12 weeks of Rx treatment. Data were
statistically analyzed using one-way ANOVA with Dunnette’s post hoc test. Data are presented as mean ± S.E.M. (n = 5-6). ** P < 0.01.
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control in db/db mice. Within 3 weeks of treatment, the
fed glucose levels were significantly reduced and this
effect was persistent throughout the treatment period
(until week 7). In order to determine whether the thera-
peutic effect of Rx would persist after drug withdrawal,
we stopped the administration of Rx for 2 weeks (week
8-10) (figure 5a). The fed blood glucose level remained
lowered for one week (week 8) after drug withdrawal
and then gradually increased from week 8 to week 10,
but was reduced again when Rx was re-administrated to
the mice (week 11-12). Similarly, the fasting glucose
levels and serum insulin concentrations were signifi-
cantly reduced in Rx-treated db/db mice (figure 5b,c).
Rx treatment also dramatically improved the hypertrigly-
ceridemia in db/db mice within 2 weeks of treatment,
with the effect lasting throughout the treatment period
and persisting through the two weeks of drug withdra-
wal (figure 5d). A trend of decreased serum free fatty
acid (FFA) was also observed (figure 5e). These data
suggested that Rx treatment could improve the glycemic
and lipid control in db/db mice.
Glucose tolerance test and insulin tolerance test were
performed to examine the systemic glucose metabolism
and insulin sensitivity in db/db mice. Rx-treated db/db
mice displayed a more efficient clearance of systemic
glucose level and had a significant increase in insulin
sensitivity than the vehicle-treated db/db mice (figure
6a, b, c, d).
Effect of Rx Treatment on the Adipose Tissue of the db/
db Diabetic Mice
Quantitative real time PCR analysis showed that chronic
treatment with Rx resulted in a significant reduction in
the mRNA levels of two macrophage markers, CD 68
and F4/80, in the epididymal adipose tissue of db/db
mice when compared with the vehicle-treated mice (fig-
ure 7a, b). The mRNA levels of the pro-inflammatory
cytokines, TNF-a and MCP-1, were also markedly
reduced in the adipose tissue of the Rx-treated mice
(figure 7c, d). In contrast, the mRNA levels of the anti-
inflammatory or “alternatively activated” macrophages
arginase I gene, was significantly increased in the Rx-
treated mice (figure 7e). These findings suggest that Rx
treatment reduced inflammation status in the adipose
tissue.
Physical Parameters in Experimental Animals
Treatment of db/db mice with Rx did not affect daily
food uptake (figure 8a). However, there was an increased
body weight in the Rx-treated group (figure 8b). This
may be due to the increased liver weight (figure 8c) and
adipocyte size (figure 9). Biochemical analysis on the
hepatic lipid profile showed that there were no signifi-
cant changes in hepatic triglyceride, cholesterol and free
fatty acid in the Rx treated mice (figure 10) when com-
pared with vehicle-treated mice.
Discussion
The prevalence of diabetes has become a major public
health concern worldwide and is known to be closely
associated with obesity. Cumulating evidence suggests
that chronic inflammation in white adipose tissue
(WAT), which is characterized by infiltrated macro-
phages and aberrant production of pro-inflammatory
cytokines, plays an essential role in linking obesity with
diabetes and its complications [18,19]. Insulin resistance
precedes impaired glucose tolerance and the onset of
type 2 diabetes. In obese subjects, infiltrated macro-
phages together with enlarged adipocytes secrete numer-
ous pro-inflammatory mediators such as IL-6 and
TNF-a, which contribute to insulin resistance [6,20].
The cytokine-stimulated adipocytes secrete chemokines
such as MCP-1 which further enhance the recruitment
of macrophages into the adipose tissue, hence amplify-
ing the inflammatory response [21-23].
Though there are existing synthetic anti-diabetic drugs
that possess anti-inflammatory properties, such as the
thiazolidenediones (TZDs), an increasing number of stu-
dies has documented their undesirable effects including
the increased risk for heart failure and bone fractures
[24]. Therefore, it is important to identify new anti-dia-
betic drug with anti-inflammatory actions that are asso-
ciated with a better safety profile. With the increased
popularity of herbal medicine, many Chinese herbs are
now frequently used as the natural and presumably safer
sources for drug discovery. Metformin, a widely used
anti-diabetic drug, was identified from the herb French
lilac (Galega officinalis) [25,26]. Berberine, identified
from the traditional herb Hydrastis canadensis or Coptis
chinensis which has been used for treating diabetes in
China for more than 1400 years, has recently been
shown to have glucose lowering, insulin sensitizing and
incretin actions [27-29].
In the present study, we have developed a high-
throughput screening platform, for selection of active
fractions from traditional Chinese herbs that possess
anti-inflammatory properties, which is based on the abil-
ity of the fraction to inhibit cytokine production in
macrophages. An effective fraction Rx from Radix Astra-
gali was identified after repeated screening and its anti-
diabetic effect was confirmed in the db/db mouse
model.
Radix Astragali is an edible herb that has been used as
one of the primary tonic herbs in China for many cen-
turies [30]. Recently, various studies on the effects of
Radix Astragali on obesity-related metabolic disorders
have been carried out [31,32]. The extracts of Radix
Astragali have been shown to be anti-inflammatory [33],
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Figure 6 Rx treatment alleviated glucose intolerance and insulin resistance in db/db diabetic mice. Male db/db diabetic mice were
treated with vehicle or Rx (2 g/kg/day) for 12 weeks by oral gavage. (a) Glucose tolerance test (GTT) conducted at week 12 after treatment. (b)
Glucose tolerance test expressed as area under curve. (c) Insulin tolerance test (ITT) conducted at week 12 after treatment. (d) Insulin tolerance
test expressed as area under curve. All mice were fasted for 16 hours or 6 hours before GTT and ITT were carried out, respectively. Data were
statistically analyzed using one-way ANOVA with Dunnette’s post hoc test. Data are presented as mean ± S.E.M. (n = 5-6). * P < 0.05; ** P < 0.01.
Figure 7 Rx inhibited the inflammatory state in adipose tissue of db/db diabetic mice. Panels show the relative mRNA levels of the
inflammatory cell markers (a) CD68 and (b) F4/80, pro-inflammatory cytokines (c) TNF-a and (d) MCP-1 and alternatively activated macrophage
marker (e) arginase I in adipose tissue of vehicle- or Rx-treated db/db diabetic mice and lean control. Data were statistically analyzed using one-
way ANOVA with Dunnette’s test. Data are presented as relative mean fold change ± S.E.M. (n = 5-6). * P < 0.05; ** P < 0.01.
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hepatoprotective [34], cardioprotective [35], neuropro-
tective [36,37] and anti-diabetic [38]. The use of Radix
Astragali to treat diabetic symptoms (Xiao Ke, or wast-
ing thirst syndrome, in Chinese medicine) has been well
documented in the Compendium of Materia Medica
(Ben Cao Gang Mu) during the Ming Dynasty (from
1368-1644 AD). Notably, Radix Astragali is now being
used as a major ingredient in six of the seven anti-
diabetic herb formulae approved by the State Drug
Administration in China [38].
Radix Astragali contains various isoflavones and isofla-
vonoids including formononetin, calycosin and ononin,
and many saponins including astragaloside I, astragalo-
side II, astragalosie VI and also acetylastragaloside I
[39]. Our laboratory has demonstrated that astragaloside
II and isoastragaloside I from Radix Astragali alleviate
insulin resistance, glucose intolerance and hyperglycemia
by increasing the secretion of the insulin sensitizing hor-
mone, adiponectin from adipocytes [17]. The effective
fraction Rx is a mixture of 4 isoflavonoids including
calycosin-7-b-D-glucoside (0.9%), ononin (1.2%), calyco-
sin (4.53%) and formononetin (1.1%). Formononetin and
calycosin have been shown to be activators of peroxi-
some proliferator-activated receptors (PPARa and
PPAR-g) [40], the major therapeutic targets of the
fibrate group of lipid-lowering drugs the TZDs, respec-
tively. It should be noted that PPAR-g is highly
expressed in the adipose tissue where it regulates insulin
sensitivity, adipocyte differentiation and lipid storage,
and is responsible for regulating the alternative activa-
tion of macrophages [41]. Formononetin and calycosin
have also been reported to potentiate the anti-hypergly-
cemic action of fangchinoline [42] and inhibit the LPS-
induced production of TNF-a, nitric oxide and superox-
ide in mesencephalic neuron glia culture [43]. On the
other hand, calycosin has a protective effect in endothe-
lial cells against hypoxia-induced barrier impairment
[44], while calycosin-7-O-b-D-glucoside and ononin
have been reported to be free radicals scavenging anti-
oxidants [45]. All these studies have suggested that the
four major components of Rx would have potential anti-
inflammatory, glucose-lowering and anti-oxidant effects
which may contribute to improving the insulin resis-
tance, glycemic and lipid control in the Rx-treated db/
db mice. However, there is no evidence suggests that
these components are bioactive ingredients. Further
experiments are needed to verify it.
The Food and Drugs Administration (FDA) is now
recommending a mixture of multiple active ingredients
rather than a single active compound for herbal alterna-
tive medicine. This is due to the fact that the constitu-
ents can work together to enhance the effectiveness and
potentiate a synergistic effect, so that the dosage and
toxicity can be reduced [46].
Our present study has demonstrated that Rx signifi-
cantly reduced the plasma glucose and triglyceride levels
with the effect persisting throughout the experimental
period (figure 5a, b, d). Rx treatment also reduced the
expression of macrophage markers and pro-inflamma-
tory cytokines in the adipose tissue, indicating an ameli-
orating effect on chronic inflammation in the db/db
Figure 8 Effects of Rx on the basic metabolic parameters of
db/db diabetic mice. Panels show (a) daily food intake, (b) body
weight and (c) liver weight of the treated db/db diabetic mice. Data
were statistically analyzed using one-way ANOVA with Dunnette’s
test. Data are presented as mean ± S.E.M. (n = 5-6). * P < 0.05; ** P
< 0.01.
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diabetic mice. The increased arginase I expression
implied an increased alternative activation of macro-
phages in the adipose tissue, which could lead to the
secretion of the anti-inflammatory cytokines IL-10 and
IL-8 [47], indicating that Rx treatment may lead to
polarization of resident macrophage towards the alterna-
tive state. Though increased body weight in db/db mice
has been observed after Rx treatment, this is also a com-
mon effect of the well-established PPAR-g agonist,
TZDs, in spite of their anti-diabetic effect.
In summary, the present study raised the possibility
that measurement of cytokine production level in
macrophages is a viable activity-guided high-throughput
screening method to search for the lead compounds
with anti-diabetic potential. Using this platform an effec-
tive fraction Rx was identified from the traditional Chi-
nese herbal medicine Radix Astragali and shown to
demonstrate anti-diabetic and lipid-lowering effects,
at least in part via the suppression of inflammation in
adipose tissue.
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